Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

25%

2 of 8 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

N/A

5(62.5%)

Phase 2

1(12.5%)

Phase 4

1(12.5%)

Phase 3

1(12.5%)

8Total

N/A(5)

Phase 2(1)

Phase 4(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT04087239Active Not Recruiting

The University of Zimbabwe College of Health Science (UZ-CHS) BIRTH COHORT Study

Role: collaborator

NCT00297882Phase 3Completed

Artemisinin-Based Combination Therapy: Clinical Trials in Cameroon

Role: collaborator

NCT00146718Phase 2Completed

Anti-Malarial Drug Resistance in Cameroon

Role: collaborator

NCT01350752Not ApplicableCompleted

Research on the Economics of Artemisinin Combination Therapy (ACTs) for the Treatment of Malaria

Role: collaborator

NCT01030458Phase 4Completed

Newer Versus Older Antihypertensive Agents in African Hypertensive Patients (NOAAH) Trial

Role: collaborator

NCT01141777Not ApplicableCompleted

The Effects of Spirulina Platensis on Insulin Resistance in HIV-infected Patients

Role: collaborator

NCT00645775Not ApplicableCompleted

Effect of Irvingia Gabonensis (Bush Mango)on Parameters Associated With Metabolic Syndrome

Role: collaborator

NCT00493506Not ApplicableCompleted

ProAlgaZyme Novel Algae Infusion: Applications in Immunodeficiency

Role: collaborator

NCT00489333Not ApplicableCompleted

ProAlgaZyme Novel Algae Infusion: Applications in Metabolic Syndrome

Role: collaborator

All 9 trials loaded